Abstract:Background Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) have been confirmed to exert therapeutic effects on systemic lupus erythematosus (SLE). Deficiency in SLE macrophages exhibits excessive activation and inefficient clearance of self nuclear antigens. However, whether the benefit effect of UCMSCs on SLE was mediated by regulatory effects on macrophages remains to be elucidated. Objectives We aim to explore whether UCMSCs could educate SLE macrophage to become a kind of alternatively activated macrophage and increase its phagocytic activity. Methods UCMSCs were injected into B6.MRL-Faslpr mice. The therapeutic effects of MSCs transplantation were evaluated by the renal pathology, proteinuria, spleen index, T lymphocyte subpopulation and plasma cells. Murine peritoneal/renal macrophages were isolated to detect the proportion of alternatively activated macrophage (F4/80+CD206+). To determine the phagocytic activity of murine peritoneal/renal macrophages, FITC-labeled flurospheres were added into the cultures. The uptake of FITC-labeled flurospheres was determined by flow cytometry. CD14+ monocytes were isolated from peripheral blood of healthy donors (HC) and SLE patients. We cultured human monocytes for 7 days with macrophage colony-stimulating factor (M-CSF) to generate macrophages, and then cocultured them for 2 more days with UCMSCs in a transwell culture system. The levels of CD206 and phagocytic activity of macrophages were detected by flow cytometry. Results Compared with C57BL/6 mice, B6.MRL-Faslpr mice macrophages exhibited lower level of CD206, the marker of alternatively activated macrophages. In addition, the phagocytic activity of B6.MRL-Faslpr mice macrophages was also decreased. UCMSCs transplantation could rescue both the proportion of CD206+ macrophages and the phagocytic activity. Interestingly, the proportion of CD206+ macrophages was positively correlated with the phagocytic activity. Similar to the lupus mice, macrophages from SLE patients showed lower expression of CD206 and phagocytic activity. SLE macrophages cocultured with UCMSCs consistently increased the expression of CD206 and phagocytic activity. In addition, the up-regulation of phagocytic activity by UCMSCs was only appeared in CD206+ macrophages. This phenomenon was also observed in UCMSCs transplanted SLE patients. Furthermore, the addition of specific neutralizing antibodies/inhibitor/siRNA of HGF, TGFβ1, PGE2 and HO-1 could not reverse the effects of UCMSCs on SLE macrophages. Conclusions UCMSCs could alleviate SLE through promoting the generation of CD206+ macrophage and increasing its phagocytic activity, and these effects was independent of HGF, TGFβ1, PGE2 and HO-1. Disclosure of Interest None declared

MCP-1 and IL-4 Encapsulated Hydrogel Particles with Macrophages Enrichment and Polarization Capabilities for Systemic Lupus Erythematosus Treatment

Bio-inspired Adhesive Porous Particles with Human MSCs Encapsulation for Systemic Lupus Erythematosus Treatment

Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus

Biomimetic liposomes hybrid with erythrocyte membrane modulate dendritic cells to ameliorate systemic lupus erythematosus

Immunized Microspheres Engineered Hydrogel Membrane for Reprogramming Macrophage and Mucosal Repair

AB0179 Mesenchymal Stem Cells Promote the Generation of CD206+ Macrophage and Increase Its Phagocytic Activity in Systemic Lupus Erythematosus

ECM-inspired peptide dendrimer microgels with human MSCs encapsulation for systemic lupus erythematosus treatment

Mesenchymal Stem Cells Prevent Podocyte Injury in Lupus-Prone B6.MRL-Faslpr Mice Via Polarizing Macrophage into an Anti-Inflammatory Phenotype

Apoptotic Cell-Mimicking Gold Nanocages Loaded with LXR Agonist for Attenuating the Progression of Murine Systemic Lupus Erythematosus.

Allogenic Umbilical Cord-Derived Mesenchymal Stromal Cells Sustain Long-Term Therapeutic Efficacy Compared with Low-Dose Interleukin-2 in Systemic Lupus Erythematosus.

Mesenchymal Stem Cells-derived Exosomes Ameliorate Lupus by Inducing M2 Macrophage Polarization and Regulatory T Cell Expansion in MRL/lpr Mice

Red Blood Cell Membrane Functionalized Biomimetic Nanoparticles for Systemic Lupus Erythematosus Treatment

Exploring pectin-casein micelles as novel carriers for oral drug delivery of artesunate in the treatment of systemic lupus erythematosus

Macrophage Differentiation and Polarization Via Phosphatidylinositol 3-Kinase/akt-erk Signaling Pathway Conferred by Serum Amyloid P Component

Mesenchymal stem cell-derived exosome-educated macrophages alleviate systemic lupus erythematosus by promoting efferocytosis and recruitment of IL-17+ regulatory T cell

Engineered Cell Membrane Vesicles Expressing CD40 Alleviate System Lupus Nephritis by Intervening B Cell Activation

Mesenchymal Stem Cells Promote CD206 Expression and Phagocytic Activity of Macrophages Through IL-6 in Systemic Lupus Erythematosus

Light-activated Extracellular Matrix Microcarriers with Engineered MSCs Loading for Autoimmune Psoriasis Treatment

Microenvironment Responsive Hydrogel Exerting Inhibition of Cascade Immune Activation and Elimination of Synovial Fibroblasts for Rheumatoid Arthritis Therapy

Macrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization

PLGA/PCADK composite microspheres containing hyaluronic acid-chitosan siRNA nanoparticles: A rational design for rheumatoid arthritis therapy